Humacyte
HUMA
Market cap $368M

2.37 USD

-0.04

1.66%

At close Jun 13, 4:00 PM EDT

After hours

2.38

+0.01

0.42%

1 day

-1.66%

5 days

-9.54%

1 month

36.99%

3 months

-14.44%

6 months

-42.20%

Year to date

-54.25%

1 year

-67.08%

5 years

-75.49%

10 years

-75.49%

About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

Employees: 220

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

47% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 38

26% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 31

6.85% more ownership

Funds ownership: 32.72% [Q4 2024] → 39.58% (+6.85%) [Q1 2025]

4% more funds holding

Funds holding: 162 [Q4 2024] → 168 (+6) [Q1 2025]

15% less call options, than puts

Call options by funds: $2.56M | Put options by funds: $3M

51% less capital invested

Capital invested by funds: $213M [Q4 2024] → $104M (-$109M) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

69%

upside

Avg. target

$14.33

505%

upside

High target

$25

955%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital Jason Kolbert	955%upside $25	Buy Maintained	9 Jun 2025
HC Wainwright & Co. Swayampakula Ramakanth	69%upside $4	Buy Assumed	14 May 2025
Benchmark Bruce Jackson	491%upside $14	Buy Maintained	14 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about HUMA published over the past 30 days

Humacyte: Revenue Ramp From Symvess Incoming

Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M annual revenue opportunity, depending on market penetration and future FDA approvals for expanded indications. Financial risks remain due to high cash burn and potential dilution, but current valuation appears reasonable given future growth prospects and insider buying.

Humacyte: Revenue Ramp From Symvess Incoming

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients at high risk of autologous arteriovenous fistula (AVF) maturation failure with end-stage renal disease were presented in a plenary session at the Society for Vascular Surgery Vascular Annual Meeting (VAM25), held in New Orleans, LA, on June 6, 2025.

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for high-risk patients with end-stage renal disease was accepted for an oral presentation at the Society for Vascular Surgery Vascular Annual Meeting (VAM25).

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Zacks Investment Research

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Founder, President and Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer and Treasurer BJ Scheessele - Chief Commercial Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen Kristen Kluska - Cantor Fitzgerald Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Humacyte's First Quarter Results Conference Call. Currently, all participants are in a listen-only mode.

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025.

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Zacks Investment Research

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

See News Rankings

Charts implemented using Lightweight Charts™